CiteScore 2024 Released: VIEW Journal Scores an Impressive 14.5!

On June 4 2025, Elsevier officially released the 2024 CiteScore, a key metric used to assess the impact of academic journals. VIEW, jointly sponsored by China Professional Community of Experimental Medicine (CPCEM) and published by John Wiley & Sons, achieved a CiteScore of 14.5 for 2024. This marks a continued upward trend from its 2023 score of 12.6, placing VIEW among the top journals in the fields of materials and engineering science. 

In the category of Engineering (Biomedical Engineering), VIEW ranks 25th out of 323 journals, climbing 2 spots from 2023. In Materials Science (Biomaterials), it ranks 15th out of 140 journals, an improvement of 5 positions compared to last year.

CiteScore

CiteScore is one of the key journal evaluation indicators in the Scopus database. It provides an assessment of over 28,100 peer-reviewed journals, book series, conference proceedings, and trade publications indexed in Scopus. Recognized by researchers, librarians, journal editors, and authors alike, CiteScore serves as a valuable reference for evaluating publication impact and supporting more informed academic decision-making.

VIEW

VIEW is a bimonthly, open-access journal co-published with Wiley, focusing on the visualization of life and health. It explores how innovative materials can integrate diagnostics and therapeutics to enable next-generation precision medicine technologies. The journal covers a broad spectrum of interdisciplinary and emerging fields, including materials science, chemistry, life sciences, medical sciences, experimental medicine, biomedical engineering, and engineering sciences.

VIEW accepts a wide range of submission types, including original research articles, reviews, communications, perspectives, analyses, and clinical case reports.